{
    "clinical_study": {
        "@rank": "35055", 
        "acronym": "CARLHA", 
        "arm_group": {
            "arm_group_label": "abiraterone", 
            "arm_group_type": "Experimental", 
            "description": "Abiraterone acetate (three dose levels in phase I) + prednisone (10mg/day)+LHRH + Radiotherapy"
        }, 
        "brief_summary": {
            "textblock": "As there is no prospective data on the combination of abiraterone and salvage radiotherapy,\n      the aim of this study is to further evaluate the safety profile of abiraterone acetate plus\n      prednisone in patients with prostate cancer who are biochemically relapsing after surgery\n      and undergo salvage radiotherapy with 6-months LH-RH agonist.\n\n      The investigators hypothesize that the toxicity profile of both treatments should not\n      potentiate each other. This study will also provide preliminary data on the efficacy of this\n      combination."
        }, 
        "brief_title": "Safety and Efficacy of Radiotherapy Combined With a 6-month LH-RH Agonist and Abiraterone Hormone Therapy Treatment in Biochemically-relapsing Prostate Cancer Following Surgery", 
        "completion_date": {
            "#text": "January 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Biochemically-relapsing Prostate Adenocarcinoma Following Radical Prostatectomy", 
        "condition_browse": {
            "mesh_term": [
                "Adenocarcinoma", 
                "Prostatic Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Histologically confirmed prostate adenocarcinoma\n\n          2. The patients should have undergone only surgery for localized prostate\n             adenocarcinoma: pT2, pT3 or pT4 with bladder neck involvement\n\n          3. pN0: negative lymphadenectomy at the time of prostatectomy\n\n          4. At inclusion the patients should have no clinical signs of progressive disease and\n             should be M0 (bone and pelvic scans).\n\n          5. \u2265 18 years of age with life expectancy \u2265 10 years\n\n          6. Performance Status (ECOG) \u2264 1\n\n          7. PSA \u2264 0.1 ng/ml after prostatectomy (dosage performed within 2 months after surgery)\n\n          8. PSA \u2265 0.2 ng/ml et \u2264 2 ng/ml at the time of inclusion\n\n          9. Elevation of PSA over three consecutive assays performed in the same laboratory, with\n             a minimal interval of two months between assays,  (PSA nadir level followed by two\n             other progressive assays)\n\n         10. At least 6 months between surgery and biochemical relapse\n\n         11. Serum potassium \u2265 3.5 mmol/L in the 72 hours before first dose of abiraterone acetate\n\n         12. Serum creatinine < 1.5 x ULN or a calculated creatinine clearance \u2265 60 mL/min\n\n         13. Liver function:\n\n             Serum bilirubin < 1.5 x ULN (except for patients with documented Gilbert's disease)\n             AST and ALT < 2.5 x ULN\n\n         14. Patients must be affiliated to a Social Security System.\n\n         15. Patient information and written informed consent form signed for both principal and\n             additional research\n\n         16. Patients must be willing and able to comply with scheduled visits, treatment plan,\n             laboratory tests and other study procedures\n\n        Exclusion Criteria:\n\n          1. pN1: histologically-proven lymph node involvement at initial lymphadenectomy\n\n          2. Histology other than adenocarcinoma\n\n          3. Previous hormone therapy including prior therapy with ketoconazole or other CYP17\n             inhibitor(s) for prostate cancer.\n\n          4. Patients being treated within the last 14 days prior to inclusion with drugs\n             recognized as being strong inhibitors or inducers of the isoenzyme CYP3A4\n             (Clarithromycin, Ketoconazole, Itraconazole, Voriconazole, Ritanovir, see appendix\n             11) or requiring those treatments during the study\n\n          5. Active or symptomatic viral hepatitis or chronic liver disease\n\n          6. Surgical or chemical castration\n\n          7. History of cancer, with the exception of basal cell carcinoma or any other cancer\n             treated in the 5 years before inclusion and in complete remission.\n\n          8. Previous pelvic radiotherapy\n\n          9. Uncontrolled hypertension (defined as systolic BP \u2265 140 mmHg or diastolic BP \u2265 90\n             mmHg). Patients with a history of hypertension are allowed provided blood pressure is\n             controlled by anti-hypertensive therapy (see appendix 10 for mandatory BP measurement\n             guidelines)\n\n         10. Severe and moderate hepatic impairment (Child-Pugh class B and C)\n\n         11. Patients with severe and/or uncontrolled medical disease which could compromise\n             participation in the study, such as, but not limited to:\n\n             Clinically significant heart disease as evidenced by myocardial infarction, or\n             arterial thrombotic events in the past 6 months, severe or unstable angina, or New\n             York Heart Association (NYHA) Class III or IV heart disease or cardiac ejection\n             fraction measurement of < 50 % at baseline\n\n         12. Known hypersensitivity to any of the study drugs or excipients.\n\n         13. Galactosemia, Glucose-galactose malabsorption or lactase deficiency\n\n         14. Patients with any psychological, sociological or geographical condition potentially\n             hampering compliance with the study protocol and follow-up schedule; those conditions\n             should be discussed with the patient before registration in the trial.\n\n         15. Individual deprived of liberty or placed under the authority of a tutor.\n\n         16. Patients already included in another therapeutic trial with an experimental drug or\n             having been given an experimental drug within a period of 30 days."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "43", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01780220", 
            "org_study_id": "GEP12-UC-0101/1104"
        }, 
        "intervention": {
            "arm_group_label": "abiraterone", 
            "description": "Abiraterone acetate 1000mg/day + prednisone alone for one month before initiating the sequence of radiotherapy", 
            "intervention_name": "Abiraterone", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "abiraterone", 
            "biochemically-relapsing", 
            "prostate adenocarcinoma"
        ], 
        "lastchanged_date": "January 29, 2013", 
        "location": [
            {
                "contact": {
                    "last_name": "Christian CARRIE, Pr"
                }, 
                "facility": {
                    "address": {
                        "city": "Lyon", 
                        "country": "France", 
                        "zip": "69373"
                    }, 
                    "name": "Centre Leon Berard"
                }, 
                "investigator": {
                    "last_name": "Christian CARRIE, Pr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "stephane.supiot@ico.unicancer.fr", 
                    "last_name": "St\u00e9phane Supiot, MD, PhD", 
                    "phone": "0240679933"
                }, 
                "facility": {
                    "address": {
                        "city": "Saint Herblain, Nantes", 
                        "country": "France", 
                        "zip": "44805"
                    }, 
                    "name": "Institut de Canc\u00e9rologie de l'ouest/Ren\u00e9 Gauducheau"
                }, 
                "investigator": {
                    "last_name": "stephane Supiot, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "other_outcome": {
            "measure": "overall safety profile", 
            "safety_issue": "Yes", 
            "time_frame": "3 years"
        }, 
        "overall_contact": {
            "email": "k-buffard@unicancer.fr", 
            "last_name": "karine buffard, Phar D"
        }, 
        "overall_contact_backup": {
            "email": "c-mahier@unicancer.fr", 
            "last_name": "C\u00e9line Mahier"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "to determine the maximum tolerated dose and the phase II recommended dose of abiraterone acetate treatment plus prednisone and LH-RH agonist combined with prostate radiotherapy", 
            "safety_issue": "Yes", 
            "time_frame": "within 11 weeks after Radiotherapy initiation"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01780220"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "To evaluate the 3-year biochemical relapse-free survival", 
            "safety_issue": "No", 
            "time_frame": "3 years"
        }, 
        "source": "UNICANCER", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "UNICANCER", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}